By San José, Costa Rica — A significant advancement in oncology is expanding treatment options for adults diagnosed with operable gastric and gastroesophageal junction cancer. The introduction of Durvalumab, an innovative immunotherapy developed by global biopharmaceutical company AstraZeneca, marks a pivotal moment in perioperative cancer care. Designed for use alongside standard chemotherapy both before and after surgical intervention, followed by monotherapy, this regimen represents a major shift toward comprehensive disease management.
This novel approach recently achieved approval from the United States Food and Drug Administration (FDA), making it the first and only immunotherapy authorized for this specific perioperative protocol. Clinical evidence supporting this authorization comes from the landmark Phase III Matterhorn study. The trial demonstrated a compelling 29% reduction in the risk of disease recurrence, progression, or death compared to standard chemotherapy alone, alongside a 22% reduction in overall mortality risk.
To analyze the legal, regulatory, and healthcare policy implications surrounding the introduction of breakthrough gastric cancer immunotherapies in Costa Rica, TicosLand.com consulted with leading legal expert Lic. Larry Hans Arroyo Vargas from the law firm Bufete de Costa Rica.
As advanced oncology treatments like immunotherapy emerge, navigating the regulatory approval process through the Ministry of Health becomes a pivotal issue. Striking a balance between protecting intellectual property rights for biopharmaceutical innovation and streamlining sanitary registration is paramount to ensuring Costa Rican patients gain timely access to life-saving therapies through both private healthcare and the Social Security Fund (CCSS).
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Lic. Arroyo Vargas rightly highlights the delicate equilibrium required between regulatory oversight and swift patient access; as gastric cancer continues to pose a significant health challenge in Costa Rica, optimizing these administrative pathways is crucial for bringing cutting-edge immunotherapies to patients across the nation. We extend our sincere gratitude to Lic. Larry Hans Arroyo Vargas for sharing his valuable perspective on this vital intersection of healthcare law and medical innovation.
Surgical resection remains the primary baseline for addressing solid tumors in the digestive system, but clinical consensus increasingly recognizes its limitations when deployed in isolation. Specialized medical professionals emphasize that multi-modal strategies are essential for improving long-term outcomes.
Surgery is the crucial pillar of treatment, but we have seen that surgery alone is not enough.
Dr. Sandra Castro Boix, Specialist in General and Digestive System Surgery
By integrating chemotherapy and, more recently, target-driven immunotherapy into surgical care, oncology specialists are seeing measurable improvements in overall patient survival rates. The primary goal of incorporating immunotherapy before and after surgery is to eradicate microscopic disease and prime the body’s immune defenses to combat remaining cancer cells.
We manage to cure more patients and prevent more of them from relapsing into this disease once we have treated them with surgery.
Dr. Sandra Castro Boix, Specialist in General and Digestive System Surgery
The introduction of advanced therapeutic options is particularly relevant for Costa Rica, where gastric cancer poses a persistent public health challenge. Globally, over 980,000 new cases are diagnosed annually, resulting in more than 641,000 deaths. Within Central America, Costa Rica registers approximately 1,000 new cases every year, while neighboring Panama reports over 620 diagnoses. Costa Rica’s incidence rate notably exceeds the global average, highlighting an urgent need for enhanced clinical intervention and diagnostic protocols.
Medical experts point out that early diagnosis remains the single most impactful factor in overall patient prognosis. Population-wide screening programs in nations like Japan and South Korea have dramatically increased survival rates, serving as an encouraging baseline for healthcare systems in Latin America.
Early detection is essential, and it is very important to perform endoscopies and biopsies at very early stages.
Dr. Sandra Castro Boix, Specialist in General and Digestive System Surgery
Gastric and gastroesophageal junction cancers are predominantly adenocarcinomas, originating in the mucous-producing cells that line the stomach wall. While the disease can strike at any age, approximately six out of ten diagnosed individuals are 65 or older, with a higher incidence observed among men. Key risk factors include smoking, regular alcohol consumption, obesity, and infection by the Helicobacter pylori bacterium. Dietary habits heavy in salted or smoked foods, sedentary lifestyles, and family history also play significant roles.
Recognizing early warning signs presents a distinct diagnostic challenge, as initial symptoms frequently mimic routine gastrointestinal discomforts such as gastritis or acid reflux. When persistent stomach pain, chronic heartburn, unexplained weight loss, fatigue, or anemia present themselves, comprehensive clinical evaluation is essential.
When these symptoms persist over time or other signs appear, such as weight loss, fatigue, or anemia, medical evaluation is required.
Dr. Sandra Castro Boix, Specialist in General and Digestive System Surgery
Over the past two decades, standard clinical approaches have evolved dramatically from surgical reliance to multi-agent combination therapies. The addition of immunotherapy marks the newest frontier in oncology, offering enhanced survival prospects for patients battling high-recurrence malignancies across Central America.
Research and evidence generation are fundamental to continue developing alternatives that can have a significant impact on the lives of patients and their families.
Dr. Andrés Rojas, Medical Director for Central America and the Caribbean at AstraZeneca
For further information, visit astrazeneca.com
About AstraZeneca:
AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals.
For further information, visit fda.gov
About U.S. Food and Drug Administration (FDA):
The U.S. Food and Drug Administration is an agency within the U.S. Department of Health and Human Services responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica has established itself as a premier legal practice, driven by an unyielding adherence to ethical standards and professional mastery. Building upon a rich history of guiding diverse clients through complex challenges, the firm continually adopts pioneering approaches to modern jurisprudence and public engagement. By actively demystifying the law and sharing critical insights with the broader public, Bufete de Costa Rica advances its foundational vision of equipping communities with the understanding needed to build a just and enlightened society.
